Regadenoson Monohydrate

[{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of South Carolina \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Medical University of South Carolina \/ Astellas Pharma"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Boston Children's Hospital | Washington University School of Medicine | Medical College of Wisconsin | Johns Hopkins University | La Jolla Institute for Allergy & Immunology | National Heart, Lung, and Blood Institute | Aste","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Boston Children's Hospital | Washington University School of Medicine | Medical College of Wisconsin | Johns Hopkins University | La Jolla Institute for Allergy & Immunology | National Heart, Lung, and Blood Institute | Aste","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Boston Children's Hospital | Washington University School of Medicine | Medical College of Wisconsin | Johns Hopkins University | La Jolla Institute for Allergy & Immunology | National Heart, Lung, and Blood Institute | Aste"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"University of Alabama at Birmingham \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Alabama at Birmingham \/ Astellas Pharma"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Northwestern University \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Northwestern University \/ Astellas Pharma"},{"orgOrder":0,"company":"GE Healthcare","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"GE Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GE Healthcare \/ Covance","highestDevelopmentStatusID":"7","companyTruncated":"GE Healthcare \/ Covance"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Chicago \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Chicago \/ Astellas Pharma"},{"orgOrder":0,"company":"Ochsner Health System","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Ochsner Health System","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ochsner Health System \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Ochsner Health System \/ Astellas Pharma"},{"orgOrder":0,"company":"University of Nebraska","sponsor":"Astellas Pharma | GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"University of Nebraska","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Nebraska \/ Astellas Pharma | GE Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"University of Nebraska \/ Astellas Pharma | GE Healthcare"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"MD Anderson Cancer Center \/ Astellas Pharma"},{"orgOrder":0,"company":"Versiti","sponsor":"Medical College of Wisconsin | La Jolla Institute for Allergy & Immunology | University of Illinois, Chicago | Oregon Health and Science University | Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Versiti","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versiti \/ Medical College of Wisconsin | La Jolla Institute for Allergy & Immunology | University of Illinois, Chicago | Oregon Health and Science University | Dana-Farber Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Versiti \/ Medical College of Wisconsin | La Jolla Institute for Allergy & Immunology | University of Illinois, Chicago | Oregon Health and Science University | Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Jewish Health \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"National Jewish Health \/ Astellas Pharma"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Mayo Clinic \/ Astellas Pharma"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Astellas Pharma"},{"orgOrder":0,"company":"Daniel S. Berman","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Daniel S. Berman","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daniel S. Berman \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Daniel S. Berman \/ Astellas Pharma"},{"orgOrder":0,"company":"Dipan Shah","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Dipan Shah","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Insert","sponsorNew":"Dipan Shah \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Dipan Shah \/ Astellas Pharma"},{"orgOrder":0,"company":"Timothy M. Bateman, MD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Timothy M. Bateman, MD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Timothy M. Bateman, MD \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Timothy M. Bateman, MD \/ Undisclosed"},{"orgOrder":0,"company":"Marvin W. Kronenberg, M.D.","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Marvin W. Kronenberg, M.D.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marvin W. Kronenberg, M.D. \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Marvin W. Kronenberg, M.D. \/ Astellas Pharma"},{"orgOrder":0,"company":"Paul Kim","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Paul Kim","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Paul Kim \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Paul Kim \/ Astellas Pharma"}]